Notice2022-12482
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
June 10, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 112 (Friday, June 10, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 112 (Friday, June 10, 2022)]
[Notices]
[Page 35562]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-12482]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Dawn Taylor-Mulneix at 301-767-5189,
or <a href="/cdn-cgi/l/email-protection#523633253c7c26332b3e3d207f3f273e3c373b2a123c3b3a7c353d24"><span class="__cf_email__" data-cfemail="c9ada8bea7e7bda8b0a5a6bbe4a4bca5a7aca0b189a7a0a1e7aea6bf">[email protected]</span></a>. Licensing information may be obtained
by communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases (NIAID),
5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Human lgA Monoclonal Antibody That Targets a Conserved Site on the
Plasmodium Falciparum Circumsporozoite Protein
Description of Technology
Scientists at NIAID have isolated MAD2-6, an IgA antibody active
against Plasmodium falciparum sporozoites, the infectious agent of
malaria. In 2019, the majority of the 229 million cases resulted from
P. falciparum infections. Because P. falciparum has a complex lifecycle
during human infection, most advanced malaria vaccine candidates and
current chemoprophylaxis drugs can confer only partial, short-term
protection in malaria-endemic areas. Thus, the MAD2-6 antibody could be
used alone or in combination with current technology.
MAD2-6 binds to a unique epitope overlapping with region I, a
functionally important region of the Plasmodium falciparum
circumsporozoite protein (PfCSP). This binding site of PfCSP is a
previously unknown target for protective antibodies, which may be
useful as a new target. Monoclonal antibodies are promising tools for
prevention of malaria and could replace or be combined with malaria
chemoprevention in areas with seasonal malaria.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as
well as for further development and evaluation under a research
collaboration.
Potential Commercial Applications
<bullet> Alternate technologies are required to address drug
resistance.
<bullet> A multi-targeted approach can combat all stages of the
parasite lifecycle.
<bullet> Prophylactic treatment for neutralization of P. falciparum
in normal or at-risk populations including pregnant women.
Competitive Advantages
<bullet> Antibodies can be effective as prophylactics, alone or in
combination with other treatments.
Development Stage
<bullet> Pre-Clinical.
Inventors: Joshua Tan Ph.D., Peter Crompton M.D., Robert Seder
M.D., Hyeseon Cho Ph.D., all of NIAID.
Publications: Tan, J., et al., ``Functional human IgA targets a
conserved site on malaria sporozoites'', Science Translational
Medicine, Vol. 13(599), 23 June 2021. <a href="https://doi.org/10.1126/scitranslmed.abg2344">https://doi.org/10.1126/scitranslmed.abg2344</a>.
Intellectual Property: HHS Reference No. E-130-2020-0-PCT-02--PCT
Application No. PCT/US2021/037571 filed on 6 June 2021.
Licensing Contact: To license this technology, please contact Dawn
Taylor-Mulneix at 301-767-5189, or <a href="/cdn-cgi/l/email-protection#d8bcb9afb6f6acb9a1b4b7aaf5b5adb4b6bdb1a098b6b1b0f6bfb7ae"><span class="__cf_email__" data-cfemail="89ede8fee7a7fde8f0e5e6fba4e4fce5e7ece0f1c9e7e0e1a7eee6ff">[email protected]</span></a>, and
reference E-130-2020.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this technology. For collaboration
opportunities, please contact Dawn Taylor-Mulneix at 301-767-5189, or
<a href="/cdn-cgi/l/email-protection#7a1e1b0d14540e1b0316150857170f16141f13023a141312541d150c"><span class="__cf_email__" data-cfemail="99fdf8eef7b7edf8e0f5f6ebb4f4ecf5f7fcf0e1d9f7f0f1b7fef6ef">[email protected]</span></a>.
Dated: June 3, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-12482 Filed 6-9-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on June 10, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.